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Ion-pairing high-performance liquid chromatography–ultraviolet (HPLC–UV) methods were developed
to determine two commonly used chelating agents, ethylenediaminetetraacetic acid (EDTA) in Abilifys (a
small molecule drug with aripiprazole as the active pharmaceutical ingredient) oral solution and die-
thylenetriaminepentaacetic acid (DTPA) in Yervoys (a monoclonal antibody drug with ipilimumab as the
active pharmaceutical ingredient) intravenous formulation. Since the analytes, EDTA and DTPA, do not
contain chromophores, transition metal ions (Cu2þ , Fe3þ) which generate highly stable metallocom-
plexes with the chelating agents were added into the sample preparation to enhance UV detection. The
use of metallocomplexes with ion-pairing chromatography provides the ability to achieve the desired
sensitivity and selectivity in the development of the method. Speciﬁcally, the sample preparation in-
volving metallocomplex formation allowed sensitive UV detection. Copper was utilized for the de-
termination of EDTA and iron was utilized for the determination of DTPA. In the case of EDTA, a gradient
mobile phase separated the components of the formulation from the analyte. In the method for DTPA,
the active drug substance, ipilimumab, was eluted in the void. In addition, the optimization of the
concentration of the ion-pairing reagent was discussed as a means of enhancing the retention of the
aminopolycarboxylic acids (APCAs) including EDTA and DTPA and the speciﬁcity of the method. The
analytical method development was designed based on the chromatographic properties of the analytes,
the nature of the sample matrix and the intended purpose of the method. Validation data were presented
for the two methods. Finally, both methods were successfully utilized in determining the fate of the
chelates.
& 2016 Xi'an Jiaotong University. Production and hosting by Elsevier B.V. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Trace heavy metal ions can be harmful to human health and
are of serious concern when existing as contaminants in food,
drinking water, cosmetics and pharmaceutical products [1,2].
In addition, heavy metal ions can often catalyze oxidations and
many other degradation reactions, leading to detrimental ef-
fects on the quality and shortened shelf life of products [3].
APCAs are the most commonly used and frequently studied
synthetic chelating agents which can form stable complexes to
“sequester” a wide variety of metal ions. These APCAs, in-
cluding widely used EDTA and DTPA, can enhance the stability
and shelf life of food, cosmetics and pharmaceutical formula-
tions by chelating with metal ions and consequentlyon and hosting by Elsevier B.V. Th
University.
.deactivating the degradation reaction pathways mediated by
the metal ions [3–5]. As a result, the stability studies must
demonstrate that the level of APCAs in pharmaceutical for-
mulations will ensure the desired product stability and quality.
Therefore, development of appropriate analytical methods to
quantitate the chelating agents in various pharmaceutical
formulations is becoming more necessary and often poses
analytical challenges.
A large number of analytical methods have been reported
for the analysis of APCAs in a variety of sample matrices, in-
cluding environmental samples, biological ﬂuids, cosmetics,
food and pharmaceutical products. These are usually chro-
matography or electrophoresis based methods including gas
chromatography (GC), HPLC, ion chromatography (IC) and ca-
pillary electrophoresis (CE). The determination of APCAs by GC
analysis often involves pre-treatment of samples by derivati-
zation of the carboxylic group using acidiﬁed alcohol to con-
vert APCAs into its methyl, ethyl, propyl or butyl esters to gainis is an open access article under the CC BY-NC-ND license
G. Wang, F.P. Tomasella / Journal of Pharmaceutical Analysis 6 (2016) 150–156 151volatility. The sample preparation procedures can be quite
complicated and time consuming [6–8]. HPLC methods usually
utilize detection of UV or mass spectrometry (MS). Highly
sensitive methods using LC/MS [9] and LC/MS/MS [10] were
reported. In both articles, ion-pairing chromatographic ap-
proach was applied to determine APCAs at very low con-
centrations with detection of MS or MS/MS. Limit of detection
(LOD) of mg/L was reached without any pre-concentration of
samples. Since APCAs carry ionizable amino- and carboxylate
groups, at appropriate pH, IC can also be applied for their
quantitation. A Dionex Application Note described the de-
termination of the μg/L concentrations of EDTA, nitriloacetic
acid (NTA), DTPA and ethylene-bis(oxyethylenenitrilo)tetra-
acetic acid (EGTA) in municipal drinking water and waste
water samples [11]. Harmsen et al. [12] reported determina-
tion of EDTA in water using anion exchange HPLC coupled with
UV detection at 258 nm after complexing EDTA with Fe3þ .
Pozdniakova et al. [13] developed a CE method to determine
free EDTA through pre-capillary complexation to convert EDTA
to Ni (II)-EDTA followed by CE determination of the negatively
charged chelate using UV detection. Laamanen et al. [14] re-
ported simultaneous determination of DTPA, EDTA and NTA by
a CE/UV method using copper (II) complexation. A number of
articles reported determination of trace level of APCAs in
natural water, food and environmental samples by using ion-
pairing reversed-phase HPLC coupled with UV-visible detector
for quantitation of APCA metellocomplexes [4,6,15–23].
Abilifys is a psychotropic drug for the treatment of schi-
zophrenia. In the Abilifys oral solution formulation, EDTA is
used as a preservative to prevent the degradation of drug ac-
tive ingredient, aripiprazole, induced by trace metals. Yervoys
is marketed to treat metastatic melanoma. Ipilimumab, the
active ingredient in Yervoys, is a monoclonal antibody with an
approximate molecular weight of 148 kD. In Yervoys in-
travenous solution formulation, DTPA serves as a stabilizer to
prevent possible trace metals from denaturing or catalyzing
the degradation of the drug active monoclonal antibody. The
structures of aripiprazole, ipilimumab, EDTA and DTPA are
shown in Fig. 1.
In this study, two ion-pairing reversed-phase HPLC–UV
methods were used to determine the concentrations of EDTA
used in Abilifys oral solution and DPTA in Yervoys in-
travenous solution formulations, respectively. The approach is
based on complexation of APCAs with metal ions before ana-
lysis by ion-pairing reversed-phase HPLC coupled with UV
detection. The analytical method will be used to evaluate the
use of a gradient versus an isocratic mobile phase in the de-
termination of an APCA in the matrices of a small molecule
and a biological formulation, respectively, to achieve the de-
sired separation, speciﬁcity and quantitation. Discussions will
include the choice of metal cations for complexation and the
effects of the ion-pairing reagent on retention of the analytes
and speciﬁcity of the sample matrix.2. Experimental
2.1. Reagents and chemicals
Abilifys oral solution and Yervoys intravenous injection
solution were obtained from Bristol-Myers Squibb (Princeton,
NJ, USA). The Abilifys oral solution contains 1.0 mg/mL of ar-
ipiprazole (active pharmaceutical ingredient), 0.5 mg/mL ofEDTA, and other excipients such as fructose (200 mg/mL),
glycerin, dl-lactic acid, methylparaben, propylene glycol, pro-
pylparaben, sodium hydroxide, sucrose (400 mg/mL), and
puriﬁed water. The oral solution is ﬂavored with natural
orange cream and other natural ﬂavors.
The Yervoys intravenous injection solution contains 5.0 mg/mL
of ipilimumab monoclonal antibody as the active pharma-
ceutical ingredient, 0.0393 mg/mL of DTPA (0.1 mM) and a few
other inactive ingredients such as mannitol, polysorbate 80,
sodium chloride, tris hydrochloride, and puriﬁed water.
Ultrapure water was obtained from a Milli-Q system (EMD
Millipore, Bedford, MA, USA). Acetonitrile (HPLC Grade) was
from EM Science (Gibbstown, NJ, USA); Cu(NO3)2 2.5H2O was
from J.T. Baker (Center Valley, PA, USA); FeCl3 (A.C.S reagent)
was from Sigma-Aldrich (St. Louis, MO, USA); 20 mM FeCl3
aqueous solution was prepared by dissolving 164.5 mg of FeCl3
in a 50 mL volumetric ﬂask with water. Phosphoric acid
aqueous solution (Analytical reagent for HPLC, ∼0.66 M) was
from Sigma-Aldrich. Tetrabutylammonium hydroxide (TBA)
aqueous solution (0.4 M) was ordered from J. T. Baker as
“Baker Analyzed”s HPLC reagent; EDTA and DTPA were
American Chemical Society (ACS) reagent grade material and
were both obtained from Sigma-Aldrich. The diluent for EDTA
was Cu(NO3)2 (1.6 mM) in water/acetonitrile (75:25, v/v); the
diluent for the DTPA was FeCl3 aqueous solution.
2.2. Instrumentation
A Waters Alliance Model 2695 (Waters Corporation, Mil-
ford, MA, USA) HPLC system consisting of a membrane de-
gasser, a quaternary gradient pump, an autosampler and a
column thermostat was used. The systemwas equipped with a
Waters Model 2487 UV–vis detector. The chromatogram col-
lecting and processing were controlled with the Waters Em-
power software package. HPLC analysis was performed using
YMC Pack Pro C18 column (50 mm4.6 mm, 3 μm; YMC Cor-
poration, Allentown, PA, USA).
2.3. Preparation of standards and sample solutions
2.3.1. Preparation of standards and sample solutions for EDTA
determination
An EDTA standard solution was prepared by dissolving
64.1 mg of EDTA disodium salt dihydrate in 1 L diluent
(1.6 mM Cu(NO3)2 in water/acetonitrile (75:25, v/v)) to obtain
an EDTA standard solution of 0.05 mg/mL.
Abilifys oral solution was diluted with the diluent (1.6 mM
Cu(NO3)2 in water/acetonitrile (75:25, v/v)) by 10 fold to ob-
tain a sample solution for EDTA determination. Both standard
and sample solutions were allowed to stand at room tem-
perature for at least 30 min before analysis.
2.3.2. Preparation of standards and sample solutions for DTPA
determination
A DTPA standard solution was prepared by dissolving
39.3 mg of DTPA with Milli-Q water in a 1 L volumetric ﬂask
containing 10 mL of 20 mM FeCl3 aqueous solution to obtain a
standard solution of 0.0393 mg/mL (0.1 mM) DTPA-Fe3þ
complex.
A 2 mL Yervoys intravenous injection solution was trans-
ferred into an HPLC vial using a pipette and then spiked with
20 μL of 20 mM FeCl3 aqueous solution. The vial was closed
and vortexed for at least 1 min. Both standard and sample
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least 30 min before analysis.2.4. Chromatographic conditions
2.4.1. Determination of EDTA in Abilifys oral solution
A buffer solution of 24 mM tetrabuylammonium phosphate,
pH 6.5 was prepared by diluting 60 mL of 0.4 M tetra-
butylammonium hydroxide to 1000 mL with Milli-Q water and
adjusting the pH to 6.5 using phosphoric acid solution.
A gradient mobile phase consisting of the tetra-
butylammonium phosphate buffer, pH 6.5 (mobile phase A)
and acetonitrile (mobile phase B) was used with the following
proﬁle: 25% B for 0–4 min, then linear gradient to 65% B at
10 min, followed by a linear return to 25% B at 15 min and a
further re-equilibration to 20 min. The detection wavelength
was set at 280 nm. The ﬂow rate was controlled at 1.0 mL/min.
The injection volume was 50 μL. The column temperature was
controlled at 30 °C.2.4.2. Determination of DTPA in Yervoys intravenous injection
solution
The chromatography for determination of DTPA in Yervoys
intravenous injection solution was performed using the same
equipment as for the determination of EDTA in Abilifys oral
solution. An isocratic run mobile phase consisted of premixed
solution of 24 mM tetrabutylammonium phosphate buffer, pH
6.5 and acetonitrile in the ratio of 80:20 (v/v). The detection
wavelength was set at 260 nm and injection volume was set at
50 μL. The ﬂow rate was 1.0 mL/min and the runtime was
10 min. The column temperature was controlled at 30 °C.Fig. 1. Chemical structures of analytes (EDTA and DTPA) and APIs (aripiprazole and ipili
solution.3. Results and discussion
The determination of APCAs by direct UV detection is
challenging since EDTA and DTPA do not contain a signiﬁcant
chromophore. In the Abilifys oral solution or the Yervoys
intravenous injection solution, the quantitation of EDTA and
DTPA, respectively, by direct spectrophotometric methods
becomes even impossible due to the lack of sensitivity or se-
lectivity due to the addition of the excipients in the
formulations.
Chromatographic methods including GC and LC are pre-
ferred for quality control (QC) analysis because both tech-
niques are well-established and quite reliable. Since APCAs
lack volatility, GC methods usually include a time-consum-
ing derivatization step, in which APCAs are converted into
their alkyl esters to enhance their volatility [6–8]. Con-
sidering the ruggedness and simplicity of operation as two
important method attributes, ion-pairing reversed-phase
HPLC coupled with UV detection presents a feasible method
development option.
Ion-pairing chromatography is well understood and has
been critically reviewed [24]. The determination of EDTA by
ion-pairing HPLC using metallocomplexes has been known for
some time [4,6,15–23]. In addition, the determination of EDTA
in pharmaceutical formulations based on HPLC has been re-
ported [5,20,21,23]. The use of metallocomplexes with ion-
pairing chromatography introduces additional variables that
require greater investigation during method development.
Since pharmaceutical formulations often contain multiple ex-
cipient components which may interfere with APCA peaks in
chromatography, selectivity is a critical consideration in
method development. In literature, we have not seen any re-
ports on controlling ion-pairing reagent concentration to
modulate peak selectivity for APCA determination in drug
formulations.mumab) in the two drug products, Abilifys oral solution and Yervoys intravenous
Fig. 2. EDTA-Cu2þ retention behavior by varying the TBA concentrations using an isocratic aqueous/acetonitrile (75:25, v/v) in the mobile phase. Note: Chromatograms 1-5
are collected with a solution containing EDTA-Cu2þ , while Chromatograms 6 and 7 are from EDTA-Cu2þ and methylparaben.
Fig. 3. Chromatogram of Abilifys oral solution with 0.5 mg/mL EDTA. (1)
EDTA-Cu2þ , (2) methylparaben, (3) propylparaben, (4) aripiprazole.
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dient and isocratic mobile phases in the determination of an
APCA in a small molecule and a biological formulation, re-
spectively. In the two examples presented here, the use of
metallocomplexes with ion-pairing reversed-phase chroma-
tography provides the ability to achieve the desired sensitivity
and selectivity. The analytical methods are designed based on
the chromatographic properties of the analytes, the nature of
the sample matrix and the intended purpose of the methods.
3.1. Analytical method for the determination of EDTA in Abilifys oral
solution
Ion-pairing reversed-phase HPLC methods, because of the
complexity of the interactions among analyte, stationary and
mobile phases during the process of separation, tend to be
difﬁcult to reproduce, transfer between laboratories, and
troubleshoot [25]. The slow equilibration of the column with
ion-pairing reagents can also create problems especially when
a gradient is used. Retention time may be irreproducible due
to perturbations to the equilibration between column sta-
tionary phase and mobile phases. Problems with baselines,
separation and quantitation may arise over the course of
testing. However, recent studies demonstrate that a full equi-
librium of the ion-pairing reagent on the column may not be
necessary in developing a robust and selective gradient elution
ion-pair chromatographic method [26].
A gradient HPLC method was developed for EDTA in Abil-
ifys oral solution with an ion-pairing reagent, TBA, in a
phosphate buffer solution at pH 6.5 as the aqueous component
of the mobile phase. The sensitivity to determine EDTA in the
formulation is achieved by adding copper (II) nitrate (Cu(NO3)2)
into the diluent which combines the chelation and sample
dilution steps. In addition, a short C18 column of 50 mm was
chosen to expedite the equilibrium and the analysis.
Abilifys oral solution causes several challenges for the
chromatographic method development. The oral solution
contains reagents which have extremely differing retention
behavior when using a conventional reversed-phase LC se-
paration method. The EDTA-Cu2þ , an ionic analyte, has very
little retention on reversed-phase LC. The preservatives, me-
thylparaben and propylparaben, are signiﬁcantly retained in
comparison to the EDTA. The aripiprazole, the active phar-
maceutical ingredient (API) in the formulation and with high
hydrophobicity, is expected to elute later in a reversed-phaseLC. As an initial approach, isocratic systems were utilized to
gain a better understanding of the retention behavior as a
function of the concentration of TBA to achieve appropriate
separation of the analyte and the sample matrix. As shown in
Fig. 2, EDTA-Cu2þ elutes at the solvent front when no ion-
pairing reagent is added, i.e., only 24 mM phosphate buffer as
the mobile phase (Chromatogram 1). However, as the TBA
buffer concentration in the mobile phase increases from 8 mM
to 20 mM (Chromatograms 2–5), the retention of EDTA-Cu2þ
decreases due to the competition of the interaction with the
stationary phase from the ions in the solution. To further es-
tablish the separation condition for the critical pair peaks of
EDTA-Cu2þ and methylparaben, Chromatograms 6 and 7 in
Fig. 2 were collected with a solution containing the mixture of
these two compounds. When the concentration of the TBA
buffer was at 8 mM, the elution of the EDTA complex ap-
proached a retention of 3 min, causing its co-elution with
methylparaben (Chromatogram 6). As noted, the EDTA-Cu2þ
complex eluted with a retention time of less than 2 min when
the TBA buffer was at 24 mM. In this condition, the peaks of
EDTA-Cu2þ and methylparaben were well separated (Chro-
matogram 7). It was also noted that the peak shape of the
EDTA complex deteriorated with decreasing ion-pairing con-
centration. In an effort to enhance peak shape and achieve the
necessary retention, the concentration of the TBA buffer in the
mobile phase was set at 24 mM. With the optimization of the
gradient, the analysis time was set at 20 min (including re-
equilibration). The elution order of the analytes is shown in
Fig. 3, which was achieved with the ﬁnal method conditions as
provided in the experimental section. It should be noted that
this method has the potential to analyze the preservatives in
Table 1
Summary of validation of the method for EDTA determination.
Validation
parameters
Results
Speciﬁcity Separation of EDTA-Cu2þ from excipients (methylparaben
and propylparaben), aripiprazole and solvent blank is
demonstrated (Fig. 3)
Linearity (0.01–
0.08 mg/mL)
Slope¼ 21,291,615, R2¼0.9997
Repeatability (n¼3) Results from three preparations: 0.5017, 0.5077,
0.5010 mg/mL; Mean 0.5035 mg/mL; %RSD 0.73
Accuracy (n¼3) 100.4%, 101.0%, 101.5%; Mean 101.0%; %RSD 0.55
Sensitivity LOD 1.5 μg/mL; LOQ 4.5 μg/mL
Solution stability When standard and sample solutions were stored at
room temperature, room light, they were good for
7 days (area change from initialo2.0% )
Table 2
Stability constants (log K) of EDTA- and DTPA-metallocomplexes [27].
Metal ion EDTA DTPA
Cu2þ 18.8 21.4
Fe2þ 14.3 16.4
Fe3þ 25.1 28.0
Hg2þ 21.7 26.7
Mg2þ 8.8 9.3
Mn2þ 13.9 15.6
Ni2þ 18.6 20.2
Pb2þ 18.0 18.8
Sr2þ 8.7 9.8
Zn2þ 16.5 18.4
Table 3
Summary of validation of the method for DTPA determination.
Validation
parameters
Results
Speciﬁcity Separation of DTPA-Fe3þ from ipilimumab and solvent
blank is demonstrated (Fig. 4)
Linearity (0.01–
0.08 mg/mL)
Slope¼ 63,511,103, R2¼1.000
Repeatability (n¼3) Results from three preparations: 0.0405, 0.0388,
0.0387 mg/mL; Mean 0.0393 mg/mL; %RSD 2.6
Accuracy (n¼3) 103.9%, 106.2%, 106.6%; Mean 105.6%; %RSD 1.4
Sensitivity LOD 1.8 μg/mL; LOQ 5.4 μg/mL
Solution stability When standard and sample solutions were stored at
room temperature, under room light, they were good
for 24 h (area change from initialo5.0%)
Fig. 4. HPLC Chromatogram of DTPA in Yervoys intravenous solution.
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method to quantitate the preservatives since the impurity
proﬁle of aripiprazole and the preservatives were quantitated
by pre-existing analytical methods. Finally, the diluent con-
tains copper nitrate which combines the chelation and sample
dilution steps which simpliﬁes the sample preparation. In
addition, acetonitrile (25%) was added into the diluent to so-
lubilize aripiprazole, which has very low aqueous solubility.
The validation of the method for EDTA determination de-
monstrated its speciﬁcity, linearity, accuracy, precision and
solution stability. The speciﬁcity was demonstrated by the
separation of EDTA from the methylparaben, propylparaben
and aripiprazole. The linearity of the EDTA response was va-
lidated from 0.01 to 0.08 mg/mL with a correlation coefﬁcient
(R2) of 0.9997. The target concentration of EDTA in the for-
mulation was 0.5 mg/mL. However, the working test solution
concentration was 0.05 mg/mL. Therefore, the linearity cov-
ered from 20% to 160% of label claim. The repeatability data
from three preparations resulted in a mean of 0.5035 mg/mL
and %RSD of 0.73. The accuracy data from three preparations of
spiking recovery from the sample matrix resulted in a mean of
101.0% and %RSD of 0.55. The sensitivity of the method (LOD
and LOQ) was demonstrated at the μg/mL level, as shown in
Table 1. The sample and standard solutions were stable for
7 days when stored at room temperature and room light. The
validation data are summarized in Table 1.
3.2. Analytical method for the determination of DTPA in Yervoys
intravenous solution
Following the successful development of the method for
EDTA determination for Abilifys oral solution, a method for
DTPA determination in Yervoys intravenous solution wasrequired and a similar approach was initiated for the method
development. The intent of the method was to quantitate the
DTPA in the monoclonal antibody intravenous formulation. As
previously stated, the DTPA is utilized as a preservative to
ensure the quality of the product. Similar to EDTA, DTPA has a
high afﬁnity to metal cations and can form strong complexes
with the cations involving the amino- and the carboxylate
groups [27]. When Cu2þ was initially tested as the chelating
metal, it was found that the peak shape was distorted probably
due to the interaction with the cations in solution by the extra
charge on the Cu2þ-DTPA complex formed. The type and
quantity of metal ions as well as the anions involved in the
process need to be considered since these factors affect the
strength of the complex formed between the metal ion and
the chelating agent. The stability or equilibrium constant (K),
expressed as log K, was determined for the complexes of EDTA,
DTPA and several metal ions as shown in Table 2 [27]. The
greater the log K values, the more tightly the metal ion bounds
to the chelating agent and the more likely that complexes are
formed even in the presence of competing ions. Therefore,
Fe3þ was selected as the chelating metal ion for the complex
with DTPA.
The sample preparation is simple and convenient. It con-
sisted of pipetting a 2 mL Yervoys intravenous solution into an
HPLC vial to which 20 μL of 20 mM FeCl3 aqueous solution was
added. The vial was capped and vortexed. The standard and
sample solutions were allowed to stand for at least 30 min
before analysis.
During the chromatographic method development, it was
initially envisioned to be a triﬂuoroacetic acid with gradient
mobile phases which is typically utilized for the separation of
G. Wang, F.P. Tomasella / Journal of Pharmaceutical Analysis 6 (2016) 150–156 155proteins. An initial gradient indicated that the monoclonal
antibody eluted with a very low organic content. As a result,
several isocratic runs were attempted with a low organic
content from 10% to 30% acetonitrile. The ﬁnal conditions
yielded an isocratic mobile phase consisting of 20% acetonitrile
and 80% aqueous with a pH of 6.5. With an isocratic ﬂow, it
was found that the antibody protein eluted at the solvent
front, showed by a clear apex at 280 nm on the UV spectrum
collected with a photodiode array detector. A possible ex-
planation for this early elution of the monoclonal antibody
protein is that the proteins are too large to penetrate the
narrow pores of the column (100 Å) and just pass by the
column with the mobile phase. Column clogging is a potential
challenge for performing reversed-phase LC for proteins.
Multiple injections demonstrated that column pressure did
not increase. Based on these ﬁndings, the analytical method is
extremely efﬁcient and does not require additional sample
preparations such as protein precipitation prior to separation.
The concentration of the TBA in the mobile phase was estab-
lished based on the learnings of the Abilifys case described in
detail above. The retention behavior of the monoclonal anti-
body and the retained DPTA complex is shown in Fig. 4. As
evident, the ipilimumab peak elutes in the void and the DTPA
complex is well retained and elutes at 3 min.
The validation of the method for DTPA determination de-
monstrated its speciﬁcity, linearity, accuracy, precision, and
solution stability. The speciﬁcity was noted by the separation
of DTPA from the ipilimumab. The linearity of the DTPA re-
sponse was validated from 0.01 to 0.08 mg/mL with a corre-
lation coefﬁcient (R2) of 1.000. The target concentration of
DTPA in the formulation is 0.039 mg/mL. Therefore, the line-
arity covered from 25% to 200% of label claim. The repeat data
from three preparations resulted in a mean assay of 0.0393mg/mL
and %RSD of 2.6. The accuracy data from three preparations of
spiking recovery from sample matrix resulted in a mean re-
covery of 105.6% and %RSD of 1.4. The sensitivity of the method
(LOD and LOQ) was demonstrated at the μg/mL level. The
sample and standard solutions were stable for 24 h when
stored at room temperature and under room light. All the
validation data are summarized in Table 3.4. Conclusion
In conclusion, two ﬁt for purpose, ion-pairing reversed-
phase HPLC methods were developed to determine EDTA in
Abilifys oral solution and DTPA in Yervoys intravenous solu-
tion drug products. TBA was added into the mobile phase to
form ion pairs with metallocomplexes of EDTA and DTPA to
enhance retention on reversed-phase HPLC columns. The
analytical method utilized gradient and isocratic mobile pha-
ses in the determination of an APCA in a small molecule and a
biological formulation, respectively. The use of metallocom-
plexes with ion-pairing chromatography provides the ability to
achieve the desired sensitivity and selectivity in the develop-
ment of the method.
Speciﬁcally, the sample preparation involving metallocom-
plex formation allows UV detection with high sensitivity.
Copper (II) was utilized for the determination of EDTA and iron
(III) was utilized for the determination of DTPA. For the de-
termination of EDTA, a gradient mobile phase separated the
components of the formulation from the analyte. In the case of
DTPA, the active drug substance, ipilimumab, was eluted in thevoid. To the best of our knowledge, there is no report on
analytical HPLC method for APCAs by direct injections of
monoclonal drug formulations. In addition, the optimization of
the concentration of the ion-pairing reagent was discussed as
a means of enhancing the retention of the APCAs and the
speciﬁcity of the method. The analytical method development
was designed based on the chromatographic properties of the
analytes, the nature of the sample matrix and the intended
purpose of the method.Acknowledgments
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